Direxion Daily Energy Bull 2X Shares ETF
ERX
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
VanEck Oil Services ETF
OIH
4
iShares US Telecommunications ETF
IYZ
5
Direxion Daily Financial Bear 3X Shares ETF
FAZ
US Stock MarketDetailed Quotes
Silexion Therapeutics (SLXN)
- 1.500
- +0.080+5.63%
Close Feb 24 15:55 ET
- 1.520
- +0.020+1.33%
Pre 08:12 ET
5.00MMarket Cap0.51P/E (TTM)
1.510High1.450Low6.38KVolume1.460Open1.420Prev Close9.35KTurnover0.21%Turnover RatioLossP/E (Static)3.33MShares26.70052wk High0.72P/B4.49MFloat Cap1.42052wk Low--Dividend TTM3.00MShs Float1830.195Historical High--Div Yield TTM4.23%Range %1.420Historical Low1.466Avg Price1Lot Size
SLXN Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
SLXN Orderflow
Unit: --
SLXN Orderflow Trend
IntradayDayWeekMonth
No Data
Silexion Therapeutics (SLXN) News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026
12 Health Care Stocks Moving In Tuesday's After-Market Session
Silexion Therapeutics (SLXN) Stock Forum
$Silexion Therapeutics (SLXN.US)$ Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
VIA GLOBENEWSWIRE
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed
Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% cancer cell inhibi...
VIA GLOBENEWSWIRE
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed
Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% cancer cell inhibi...
1
$Silexion Therapeutics (SLXN.US)$
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Tuesday, 16th December at 8:40 am
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed
Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% c...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Tuesday, 16th December at 8:40 am
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed
Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% c...
2
$Silexion Therapeutics (SLXN.US)$ Reuters
1m
Silexion Therapeutics Receives Positive Feedback From German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
1m
Silexion Therapeutics Receives Positive Feedback From German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
1
$Silexion Therapeutics (SLXN.US)$ Reuters
just
Silexion Therapeutics Successfully Completes Toxicology Studies for Sil204, Next-Generation Rna Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
just
Silexion Therapeutics Successfully Completes Toxicology Studies for Sil204, Next-Generation Rna Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
1
$Silexion Therapeutics (SLXN.US)$ nobody is going to shit about their news anymore.. looks reallt rubbish
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)